



ZOETIS PRESENTS NEW SCIENTIFIC DATA AT 2014 NAVDF

Presentations and grant awards illustrate company's continuing commitment to dermatology

FLORHAM PARK, N.J., April 8, 2014 — Zoetis will offer two oral presentations and one poster presentation featuring data on APOQUEL[®] (ocloclatinib tablet), the first and only Janus kinase (JAK) inhibitor approved for veterinary use during the North American Veterinary Dermatology Forum (NAVDF) in Phoenix, Ariz., April 9–12.

At the conference, the company will also award three Excellence in Dermatology™ Research Grants. The goal of this annual grant program is to support research in the area of basic science diagnosing and treating dermatologic conditions in dogs and cats.

“Zoetis is committed to research and development programs that address the real world challenges veterinarians face every day,” said Catherine Knupp, DVM, MS, executive vice president and president, Research and Development, Zoetis. “Our scientists are focusing on finding innovative solutions to the unmet needs of our veterinary customers. APOQUEL is an example of a novel treatment that safely and effectively addresses skin conditions frequently seen by veterinarians, that also helps enhance the quality of life of their clients and patients.”

Data Presented at NAVDF

- | | |
|-----------------|---|
| 4/10, 4:15 p.m. | “Efficacy and safety of oclacitinib (APOQUEL) compared to prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs” |
| 4/10, 4:30 p.m. | “Efficacy and safety of oclacitinib (APOQUEL) compared to cyclosporine (Atopica, Novartis Animal Health) for the control of atopic dermatitis in client-owned dogs” |

The above oral presentations will take place in the Phoenix Ballroom D/E. The poster presentation, “PK/PD of oclacitinib (APOQUEL) in an IL-31 induced model of pruritus in the dog,” will be on display in Phoenix Ballroom C.

As Zoetis continues to invest in research to identify innovative solutions for unmet needs, exploratory research will also be presented evaluating the role of alternative mechanisms in pruritus associated with allergic skin disease using a canine model of flea allergic dermatitis.

2014 Excellence in Dermatology Grant Recipients

Jennifer Schissler Pendergraft, DVM, MS, DACVD, and co-investigator Andrew Simpson, DVM, of Colorado State University James L. Voss Veterinary Teaching Hospital, will receive a grant for their project, “Frequency of urinary tract infection in dogs treated with oclacitinib (APOQUEL) for cutaneous hypersensitivity: a prospective study.”

A second grant is awarded to Rosanna Marsella, DVM, DACVD, and co-investigators Ha Jung Kim, DVM, PhD, and Dunbar Gram, DVM, DACVD, of the University of Florida, for “Investigation of the effect of oclacitinib on Thymic Stromal Lymphopoietin expression, skin barrier function and ability to prevent allergic sensitization in atopic dogs.”

Douglas DeBoer, DVM, DACVD, of the University of Wisconsin Madison, receives a grant to study “Serum Vitamin D levels in dogs with atopic dermatitis.”

The grant recipients will be recognized at the NAVDF on Thursday, April 10, at 11:00 a.m.

More information about Excellence in Dermatology is available at www.excellencein dermatology.com, and information about APOQUEL can be found at www.apoquel.com.

Important Safety Information

Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infections or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines. For more information, see [full Prescribing Information](#).

About Zoetis

Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenues of \$4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 28 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. For more information, visit www.zoetis.com.

Zoetis is the proud sponsor with the Smithsonian Institution Traveling Exhibition Service, the American Veterinary Medical Association, and the American Veterinary Medical Foundation of the mobile educational exhibit *Animal Connections: Our Journey Together*. Families visiting the exhibit will explore the vast bonds between people and animals and learn about the important role veterinarians play in protecting animal and human health. For more information, visit <https://www.zoetis.com/animal-connections-tour>.

For further information, Contact:

Edith Benzimra

Zoetis

973-822-7052

Edith.Benzimra@zoetis.com

Julie Lux
archer>malmo
901-500-7063
jlux@archermalmo.com



Copyright © Zoetis 2013-2014. All rights reserved. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.